Global week ahead: Is Novo Nordisk past 'peak uncertainty'?

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

The Motley Fool: Novo Nordisk has growth potential and dividend yield

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company boasts a strong pipeline of products in development, solid revenue growth and ...
New Jersey 101.5

Novo Nordisk quietly cuts over 800 jobs at New Jersey U.S. headquarters

Novo Nordisk cuts over 800 jobs in Plainsboro, part of a global restructuring under the new CEO, reflecting a troubling trend ...

Novo Nordisk layoffs: Pharma major notifies employees impacted by 9,000 job cuts amid restructuring drive

Novo Nordisk layoffs: Denmark-based pharmaceuticals major, Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar, on ...

Eli Lilly’s Sterling Results Highlight Rival Novo Nordisk’s Fading Fortunes

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner

Despite all that, there are some good reasons to consider buying into Novo Nordisk -- and the best is its low valuation, given its growth potential. The stock's recent price-to-earnings (P/E) ratio of ...